scholarly journals Caffeine increases performance and leads to a cardioprotective effect during intense exercise in cyclists

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Felipe Sampaio-Jorge ◽  
Anderson Pontes Morales ◽  
Rafael Pereira ◽  
Thiago Barth ◽  
Beatriz Gonçalves Ribeiro

AbstractThe present study was designed to investigate the effects of different caffeine dietary strategies to compare the impact on athletic performance and cardiac autonomic response. The order of the supplementation was randomly assigned: placebo(4-day)-placebo(acute)/PP, placebo(4-day)-caffeine(acute)/PC and caffeine(4-day)-caffeine(acute)/CC. Fourteen male recreationally-trained cyclists ingested capsules containing either placebo or caffeine (6 mg kg−1) for 4 days. On day 5 (acute), capsules containing placebo or caffeine (6 mg kg−1) were ingested 60 min before completing a 16 km time-trial (simulated cycling). CC and PC showed improvements in time (CC vs PP, Δ − 39.3 s and PC vs PP, Δ − 43.4 s; P = 0.00; ƞ2 = 0.33) and in output power (CC vs PP, Δ 5.55 w and PC vs PP, Δ 6.17 w; P = 0.00; ƞ2 = 0.30). At the final of the time-trial, CC and PC exhibited greater parasympathetic modulation (vagal tone) when compared to the PP condition (P < 0.00; ƞ2 = 0.92). Our study provided evidence that acute caffeine intake (6 mg∙kg−1) increased performance (time-trial) and demonstrated a relevant cardioprotective effect, through increased vagal tone.

2021 ◽  
Author(s):  
Felipe Sampaio-Jorge ◽  
Anderson Pontes Morales ◽  
Rafael Pereira de Paula ◽  
Thiago Barth ◽  
Beatriz Gonçalves Ribeiro

Abstract The present study was designed to investigate the effects of different caffeine dietary strategies to compare the impact on athletic performance and cardiac autonomic response. The order of the supplementation was randomly assigned: placebo(4-day)-placebo(acute)/PP, placebo(4-day)-caffeine(acute)/PC and caffeine(4-day)-caffeine(acute)/CC. Fourteen male recreationally-trained cyclists ingested capsules containing either placebo or caffeine (6 mg∙kg − 1) for 4 days. On day 5 (acute), capsules containing placebo or caffeine (6 mg∙kg − 1) were ingested 60 min before completing a 16km time-trial. CC and PC showed improvements in time (CC vs PP, Δ -39.3 s and PC vs PP, Δ -43.4 s; p = 0.00; ƞ2=0.33) and in output power (CC vs PP, Δ 5.55 w and PC vs PP, Δ 6.17 w; p = 0.00; ƞ2=0.30). At the final of the time-trial, CC and PC exhibited greater parasympathetic modulation (vagal tone) when compared to the PP condition (p < 0.00; ƞ2=0.92). Our study provided evidence that acute caffeine intake (6 mg∙kg − 1) increased performance and demonstrated a relevant cardioprotective effect, through increased vagal tone.


2021 ◽  
Vol 2 (1) ◽  
pp. e00143322
Author(s):  
Fernando Rodrigues ◽  
Julien Diogo ◽  
Carla Rodrigues ◽  
Cláudia Figueira ◽  
Pedro J. Rosa

Coffee is consumed worldwide, but there are different types of espresso blends, each with its unique concentration of caffeine, which can have different effects on the human being. The aim of this study was to understand the effect of the impact of caffeine on the autonomic nervous system, evaluating the physiological changes and subjective responses due to different levels of caffeine intake. A double-blind tasting task consisting of one within-subject factor design (caffeine level: high / double caffeine mixture (blend A) vs single-charge caffeine mixture (blend B) vs low-caffeine mixture (blend c) allowed us to assess participants’ autonomic responses using Heart Rate Variability (HRV) and Pupillary Reactivity (PR). Arousal was also assessed through the Self-Assessment Manikin (SAM). Results revealed statistically significant differences in HRV and PR between coffee blends, showing the blend A,a more pronounced autonomic response that blend C. However, no significant differences were found in arousal level among coffee blends. These results are similar to previous research that pointed out to a discordance between subjective and objective measures when caffeine is consumed.


2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 340.2-341
Author(s):  
V. Orefice ◽  
F. Ceccarelli ◽  
C. Barbati ◽  
R. Lucchetti ◽  
G. Olivieri ◽  
...  

Background:Systemic lupus erythematosus (SLE) is an autoimmune disease mainly affecting women of childbearing age. The interplay between genetic and environmental factors may contribute to disease pathogenesis1. At today, no robust data are available about the possible contribute of diet in SLE. Caffeine, one of the most widely consumed products in the world, seems to interact with multiple components of the immune system by acting as a non-specific phosphodiesterase inhibitor2.In vitrodose-dependent treatment with caffeine seems to down-regulate mRNA levels of key inflammation-related genes and similarly reduce levels of different pro-inflammatory cytokines3.Objectives:We evaluated the impact of caffeine consumption on SLE-related disease phenotype and activity, in terms of clinimetric assessment and cytokines levels.Methods:We performed a cross-sectional study, enrolling consecutive patients and reporting their clinical and laboratory data. Disease activity was assessed by SLE Disease Activity Index 2000 (SLEDAI-2k)4. Caffeine intake was evaluated by a 7-day food frequency questionnaire, including all the main sources of caffeine. As previously reported, patients were divided in four groups according to the daily caffeine intake: <29.1 mg/day (group 1), 29.2-153.7 mg/day (group 2), 153.8-376.5 mg/day (group 3) and >376.6 mg/day (group 4)5. At the end of questionnaire filling, blood samples were collected from each patient to assess cytokines levels. These were assessed by using a panel by Bio-Plex assays to measure the levels of IL-6, IL-10, IL-17, IL-27, IFN-γ, IFN-α and Blys.Results:We enrolled 89 SLE patients (F/M 87/2, median age 46 years, IQR 14; median disease duration 144 months, IQR 150). The median intake of caffeine was 195 mg/day (IQR 160.5). At the time of the enrollment, 8 patients (8.9%) referred a caffeine intake < 29.1 mg/day (group 1), 27 patients (30.3%) between 29.2 and 153.7 mg/day (group 2), 45 patients (51%) between 153.8 and 376.5 mg/day (group 3) and 9 patients (10.1%) >376.6 mg/day (group 4). A negative correlation between the levels of caffeine and disease activity, evaluated with SLEDAI-2K, was observed (p=0.01, r=-0.26). By comparing the four groups, a significant higher prevalence of lupus nephritis, neuropsychiatric involvement, haematological manifestations, hypocomplementemia and anti-dsDNA positivity was observed in patients with less intake of caffeine (figure 1 A-E). Furthermore, patients with less intake of caffeine showed a significant more frequent use of glucocorticoids [group 4: 22.2%,versusgroup 1 (50.0%, p=0.0001), group 2 (55.5%, p=0.0001), group 3 (40.0%, p=0.009)]. Moving on cytokines analysis, a negative correlation between daily caffeine consumption and serum level of IFNγ was found (p=0.03, r=-0.2) (figure 2A); furthermore, patients with more caffeine intake showed significant lower levels of IFNα (p=0.02, figure 2B), IL-17 (p=0.01, figure 2C) and IL-6 (p=0.003, figure 2D).Conclusion:This is the first report demonstrating the impact of caffeine on SLE disease activity status, as demonstrated by the inverse correlation between its intake and both SLEDAI-2k values and cytokines levels. Moreover, in our cohort, patients with less caffeine consumption seems to have a more severe disease phenotype, especially in terms of renal and neuropsychiatric involvement. Our results seem to suggest a possible immunoregulatory dose-dependent effect of caffeine, through the modulation of serum cytokine levels, as already suggested byin vitroanalysis.References:[1]Kaul et alNat. Rev. Dis. Prim.2016; 2. Aronsen et alEurop Joul of Pharm2014; 3. Iris et alClin Immun.2018; 4. Gladman et al J Rheumatol. 2002; 5. Mikuls et alArth Rheum2002Disclosure of Interests:Valeria Orefice: None declared, Fulvia Ceccarelli: None declared, cristiana barbati: None declared, Ramona Lucchetti: None declared, Giulio Olivieri: None declared, enrica cipriano: None declared, Francesco Natalucci: None declared, Carlo Perricone: None declared, Francesca Romana Spinelli Grant/research support from: Pfizer, Consultant of: Novartis, Gilead, Lilly, Sanofi, Celgene, Speakers bureau: Lilly, cristiano alessandri Grant/research support from: Pfizer, Guido Valesini: None declared, Fabrizio Conti Speakers bureau: BMS, Lilly, Abbvie, Pfizer, Sanofi


2016 ◽  
Vol 10 (6) ◽  
pp. 21
Author(s):  
Amir Torkashvand

This study seeks to influence environment sports on the performance of athletes. Applied research is a descriptive survey. The population consisted of high-level of athletes in martial disciplines in Tehran (3 sports gym) were estimated at around 158 people. 113 athletes have been invited to respond to the questionnaire that they use randomly chosen sample of the population by Cochran formula. A questionnaire was used for data collection. The questionnaire consists of 3 parts. The first part included demographic information and the second part of the questionnaire contains 12 questions, including questions of appearance and the third part is consist of the standard questionnaire strategic performance of Thomas. Relaiability of questionnaire is achived with experts and stability of it was 0,966 by using of Cronbach's alpha coefficient in e SPSS software. The results show that the apparent and qualitative factors are directly affecting the performance of athletes.


2017 ◽  
Vol 12 (5) ◽  
pp. 684-689 ◽  
Author(s):  
Joseph A. McQuillan ◽  
Deborah K. Dulson ◽  
Paul B. Laursen ◽  
Andrew E. Kilding

Purpose:To determine the effect of dietary nitrate (NO3 –) supplementation on physiology and performance in well-trained cyclists after 6–8 d of NO3 – supplementation.Methods:Eight competitive male cyclists (mean ± SD age 26 ± 8 y, body mass 76.7 ± 6.9 kg, VO2peak 63 ± 4 mL · kg–1 · min–1) participated in a double-blind, placebo-controlled, crossover-design study in which participants ingested 70 mL of beetroot juice containing ~4 mmol NO3 – (NIT) or a NO3 –-depleted placebo (PLA), each for 8 d. Replicating pretreatment measures, participants undertook an incremental ramp assessment to determine VO2peak and first (VT1) and second (VT2) ventilatory thresholds on d 6 (NIT6 and PLA6), moderate-intensity cycling economy on d 7 (NIT7 and PLA7), and a 4-km time trial (TT) on d 8 (NIT8 and PLA8).Results:Relative to PLA, 6 d of NIT supplementation produced unclear effects for VO2peak (mean ± 95% confidence limit: 1.8% ± 5.5%) and VT1 (3.7% ± 12.3%) and trivial effects for both VT2 (–1.0% ± 3.0%) and exercise economy on d 7 (–1.0% ± 1.6%). However, effects for TT performance time (–0.7% ± 0.9%) and power (2.4% ± 2.5%) on d 8 were likely beneficial.Conclusions:Despite mostly unclear outcomes for standard physiological determinants of performance, 8 d of NO3 – supplementation resulted in likely beneficial improvements to 4-km TT performance in well-trained male endurance cyclists.


2015 ◽  
Vol 49 (1) ◽  
pp. 209-217 ◽  
Author(s):  
Felipe García-Pinillos ◽  
Víctor Manuel Soto-Hermoso ◽  
Pedro Ángel Latorre-Román

Abstract This study aimed to describe the acute impact of extended interval training (EIT) on physiological and thermoregulatory levels, as well as to determine the influence of athletic performance and age effect on the aforementioned response in endurance runners. Thirty-one experienced recreational male endurance runners voluntarily participated in this study. Subjects performed EIT on an outdoor running track, which consisted of 12 runs of 400 m. The rate of perceived exertion, physiological response through the peak and recovery heart rate, blood lactate, and thermoregulatory response through tympanic temperature, were controlled. A repeated measures analysis revealed significant differences throughout EIT in examined variables. Cluster analysis grouped according to the average performance in 400 m runs led to distinguish between athletes with a higher and lower sports level. Cluster analysis was also performed according to age, obtaining an older group and a younger group. The one-way analysis of variance between groups revealed no significant differences (p≥0.05) in the response to EIT. The results provide a detailed description of physiological and thermoregulatory responses to EIT in experienced endurance runners. This allows a better understanding of the impact of a common training stimulus on the physiological level inducing greater accuracy in the training prescription. Moreover, despite the differences in athletic performance or age, the acute physiological and thermoregulatory responses in endurance runners were similar, as long as EIT was performed at similar relative intensity.


Author(s):  
Emily Chappelear ◽  
Cassa Drury

Many people rely on caffeine as part of their daily routine to induce the feeling of wakefulness. However, the effects of caffeine on various brain functions, such as memory, remains unclear. To study the impact of caffeine on memory and attention, we conducted a pilot study on individuals with varying levels of caffeine consumption. Each individual completed a survey, memory test, and reaction time test. The results did not elucidate clear trends or significant differences between those who consumed caffeine and those who did not. This study suggests that caffeine intake does not have a direct impact on memory, but a correlation between reaction time variability and memory suggested that more research could provide deeper insights into the effects of various levels of caffeine consumption.


2020 ◽  
Vol 128 (2) ◽  
pp. 390-396 ◽  
Author(s):  
Karleigh E. Bradbury ◽  
Beau R. Yurkevicius ◽  
Katherine M. Mitchell ◽  
Kirsten E. Coffman ◽  
Roy M. Salgado ◽  
...  

Acetazolamide (AZ) is a medication commonly used to prevent acute mountain sickness (AMS) during rapid ascent to high altitude. However, it is unclear whether AZ use impairs exercise performance; previous literature regarding this topic is equivocal. The purpose of this study was to evaluate the impact of AZ on time-trial (TT) performance during a 30-h exposure to hypobaric hypoxia equivalent to 3,500-m altitude. Ten men [sea-level peak oxygen consumption (VO2peak): 50.8 ± 6.5 mL·kg−1·min−1; body fat %: 20.6 ± 5.2%] completed 2 30-h exposures at 3,500 m. In a crossover study design, subjects were given 500 mg/day of either AZ or a placebo. Exercise testing was completed 2 h and 24 h after ascent and consisted of 15-min steady-state treadmill walking at 40%–45% sea-level VO2peak, followed by a 2-mile self-paced treadmill TT. AMS was assessed after ~12 h and 22 h at 3,500 m. The incidence of AMS decreased from 40% with placebo to 0% with AZ. Oxygen saturation was higher ( P < 0.05) in AZ versus placebo trials at the end of the TT after 2 h (85 ± 3% vs. 79 ± 3%) and 24 h (86 ± 3% vs. 81 ± 4%). There was no difference in time to complete 2 miles between AZ and PL after 2 h (20.7 ± 3.2 vs. 22.7 ± 5.0 min, P > 0.05) or 24 h (21.5 ± 3.4 vs. 21.1 ± 2.9 min, P > 0.05) of exposure to altitude. Our results suggest that AZ (500 mg/day) does not negatively impact endurance exercise performance at 3,500 m. NEW & NOTEWORTHY To our knowledge, this is the first study to examine the impact of acetazolamide (500 mg/day) versus placebo on self-paced, peak-effort exercise performance using a short-duration exercise test in a hypobaric hypoxic environment with a repeated-measures design. In the present study, acetazolamide did not impact exercise performance after 2-h or 24-h exposure to 3,500-m simulated altitude.


Author(s):  
Espen Tønnessen ◽  
Jonny Hisdal ◽  
Bent R. Ronnestad

Purpose: To determine the impact of interval training frequency in elite endurance athletes. It was hypothesized that two longer sessions would elicit greater performance improvements and physiological adaptation than four shorter sessions at the same intensity. Methods: Elite cross-country skiers and biathletes were randomly assigned to either a high-frequency group (HF group) (5 M, 1 F, age 22 (19–26), VO2max 67.8 (65.5–70.2) mL/kg/min) doing four short interval sessions per week or a low-frequency group (LF group) (8 M, 1 F, age 22 (18–23), VO2max 70.7 (67.0–73.9) mL/kg/min) doing two longer interval sessions. All interval sessions were performed at ~85% of maximum heart rate, and groups were matched for total weekly training volume. Pre- and post-intervention, athletes completed an 8 km rollerski time-trial, maximal oxygen uptake (VO2max) test, and an incremental, submaximal exercise test. Results: The LF group had a statistically significant improved time-trial performance following the intervention (p = 0.04), with no statistically significant changes in the HF group. Similarly, percentage utilization of VO2max at anaerobic threshold (p = 0.04) and exercise economy (p = 0.01) were statistically significantly improved following the intervention in the LF group only. No statistically significant changes in VO2max were observed in either group. Conclusions: Two longer interval sessions appear superior to four shorter sessions per week in promoting endurance adaptations and performance improvements in elite endurance athletes. Despite matched training volume and exercise intensity, the larger, more concentrated exercise stimulus in the LF group appears to induce more favorable adaptations. The longer time between training sessions in the LF group may also have allowed athletes to recover more effectively and better “absorb” the training. These findings are in line with the “best practice” observed by many of the world’s best endurance athletes.


Sign in / Sign up

Export Citation Format

Share Document